🎉 M&A multiples are live!
Check it out!

Opus Genetics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Opus Genetics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Opus Genetics Overview

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.


Founded

2018

HQ

United States of America
Employees

18

Website

opusgtx.com

Financials

LTM Revenue $11.6M

LTM EBITDA n/a

EV

$8.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Opus Genetics Financials

Opus Genetics has a last 12-month revenue of $11.6M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Opus Genetics achieved revenue of $11.0M and an EBITDA of -$57.5M.

Opus Genetics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Opus Genetics valuation multiples based on analyst estimates

Opus Genetics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $19.0M $11.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$10.0M -$57.5M XXX XXX XXX
EBITDA Margin -52% -523% XXX XXX XXX
Net Profit $17.9M -$10.0M XXX XXX XXX
Net Margin 94% -91% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Opus Genetics Stock Performance

As of April 15, 2025, Opus Genetics's stock price is $1.

Opus Genetics has current market cap of $38.8M, and EV of $8.5M.

See Opus Genetics trading valuation data

Opus Genetics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$8.5M $38.8M XXX XXX XXX XXX $-1.79

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Opus Genetics Valuation Multiples

As of April 15, 2025, Opus Genetics has market cap of $38.8M and EV of $8.5M.

Opus Genetics's trades at 0.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Opus Genetics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Opus Genetics and 10K+ public comps

Opus Genetics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $8.5M XXX XXX XXX
EV/Revenue 0.8x XXX XXX XXX
EV/EBITDA -0.1x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Opus Genetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Opus Genetics Valuation Multiples

Opus Genetics's NTM/LTM revenue growth is 47%

Opus Genetics's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $2.5M for the same period.

Over next 12 months, Opus Genetics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Opus Genetics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Opus Genetics and other 10K+ public comps

Opus Genetics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -42% XXX XXX XXX XXX
EBITDA Margin -523% XXX XXX XXX XXX
EBITDA Growth 477% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -476% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $2.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 166% XXX XXX XXX XXX
R&D Expenses to Revenue 244% XXX XXX XXX XXX
Opex to Revenue 410% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Opus Genetics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Opus Genetics M&A and Investment Activity

Opus Genetics acquired  XXX companies to date.

Last acquisition by Opus Genetics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Opus Genetics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Opus Genetics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Opus Genetics

When was Opus Genetics founded? Opus Genetics was founded in 2018.
Where is Opus Genetics headquartered? Opus Genetics is headquartered in United States of America.
How many employees does Opus Genetics have? As of today, Opus Genetics has 18 employees.
Who is the CEO of Opus Genetics? Opus Genetics's CEO is Dr. George Magrath, PhD.
Is Opus Genetics publicy listed? Yes, Opus Genetics is a public company listed on NAS.
What is the stock symbol of Opus Genetics? Opus Genetics trades under IRD ticker.
When did Opus Genetics go public? Opus Genetics went public in 2020.
Who are competitors of Opus Genetics? Similar companies to Opus Genetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Opus Genetics? Opus Genetics's current market cap is $38.8M
What is the current revenue of Opus Genetics? Opus Genetics's last 12-month revenue is $11.6M.
What is the current EV/Revenue multiple of Opus Genetics? Current revenue multiple of Opus Genetics is 0.7x.
What is the current revenue growth of Opus Genetics? Opus Genetics revenue growth between 2023 and 2024 was -42%.
Is Opus Genetics profitable? Yes, Opus Genetics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.